Evidence-based Modification of Intratympanic Gentamicin Injections in Patients with Intractable Vertigo

Overview

Journal Otol Neurotol

Specialties Neurology
Otorhinolaryngology

Date 2010 Apr 16

PMID 20393376

Citations 9

Authors

Feng Zhai

Jian-Ping Liu

Chun-Fu Dai

Qi Wang

Peter S Steyger

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare the cochlear distribution of low-dose fluorescent gentamicin after intra-tympanic administration in guinea pig (GPs) with clinical data of low dose intra-tympanic gentamicin in patients with intractable vertigo.

Materials And Methods: Purified gentamicin-Texas Red (GTTR) was injected intratympanically into GPs and the cochlear distribution and time course of GTTR fluorescence in outer hair cells (OHCs) was determined using confocal microscopy.

Results: GTTR was rapidly taken up by OHCs, particularly in the subcuticular zone. GTTR was distributed in the cochlea in a decreasing baso-apical gradient, and was retained within OHCs without significant decrease in fluorescence until 4 weeks after injection.

Conclusion: OHCs rapidly take up GTTR after intra-tympanic administration with slow clearance.

Clinical Application: A modified low-dose titration intratympanic approach was applied to patients with intractable Ménière's Disease (MD) based on our animal data and the clinical outcome was followed. After the modified intratympanic injections for MD patients, vertigo control was achieved in 89% patients, with hearing deterioration identified in 16% patients. The 3-week interval titration injection technique thereby had a relatively high vertigo control rate with a low risk of hearing loss, and is a viable alternative to other intratympanic injection protocols.

Citing Articles

[A case report of middle ear cholesteatoma complicated with labyrinthine fistulaand delayed endolymphatic hydrops].

Lin F, Wu Q, Zhang Y, Dai C Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023; 37(8):670-672.

PMID: 37551579 PMC: 10645530. DOI: 10.13201/j.issn.2096-7993.2023.08.015.

Skull-vibration-induced nystagmus test in patients who are candidates for intratympanic gentamicin injection.

Ciacca G, Di Giovanni A, Califano L, Pettorossi V, Ricci G, Pelliccia C Acta Otorhinolaryngol Ital. 2023; 43(2):140-148.

PMID: 37099438 PMC: 10132480. DOI: 10.14639/0392-100X-N2152.

Cochleo-facial corridor to the vestibule and fundus of the internal auditory canal through oval window: a minimal invasive and cochlea sparing approach.

Talas D, Beger O, Vayisoglu Y, Hamzaoglu V, Ozalp H, Cakir S Eur Arch Otorhinolaryngol. 2021; 279(2):627-637.

PMID: 33595698 DOI: 10.1007/s00405-021-06680-1.

Vestibular results after intratympanic gentamicin therapy in disabling Menière's disease.

Junet P, Karkas A, Dumas G, Quesada J, Schmerber S Eur Arch Otorhinolaryngol. 2016; 273(10):3011-8.

PMID: 26780342 DOI: 10.1007/s00405-015-3889-x.

Sensory hair cell death and regeneration in fishes.

Monroe J, Rajadinakaran G, Smith M Front Cell Neurosci. 2015; 9:131.

PMID: 25954154 PMC: 4404912. DOI: 10.3389/fncel.2015.00131.

References

Hoffer M, Allen K, Kopke R, Weisskopf P, Gottshall K, Wester D . Transtympanic versus sustained-release administration of gentamicin: kinetics, morphology, and function. Laryngoscope. 2001; 111(8):1343-57. DOI: 10.1097/00005537-200108000-00007. View

Minor L . Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy. Am J Otol. 1999; 20(2):209-19. View

Bauer P, MacDONALD C, Cox L . Intratympanic gentamicin therapy for vertigo in nonserviceable ears. Am J Otolaryngol. 2001; 22(2):111-5. DOI: 10.1053/ajot.2001.22569. View

Reid C, Eisenberg R, Halmagyi G, Fagan P . The outcome of vestibular nerve section for intractable vertigo: the patient's point of view. Laryngoscope. 1996; 106(12 Pt 1):1553-6. DOI: 10.1097/00005537-199612000-00022. View

KIMURA R, Lee K, Nye C, Trehey J . Effects of systemic and lateral semicircular canal administration of aminoglycosides on normal and hydropic inner ears. Acta Otolaryngol. 1991; 111(6):1021-30. DOI: 10.3109/00016489109100751. View

De Stefano A, Dispenza F, De Donato G, Caruso A, Taibah A, Sanna M . Intratympanic gentamicin: a 1-day protocol treatment for unilateral Meniere's disease. Am J Otolaryngol. 2007; 28(5):289-93. DOI: 10.1016/j.amjoto.2006.09.009. View

Plontke S, Mynatt R, Gill R, Borgmann S, Salt A . Concentration gradient along the scala tympani after local application of gentamicin to the round window membrane. Laryngoscope. 2007; 117(7):1191-8. PMC: 2728588. DOI: 10.1097/MLG.0b013e318058a06b. View

Casani A, Nuti D, Sellari Franceschini S, Gaudini E, Dallan I . Transtympanic gentamicin and fibrin tissue adhesive for treatment of unilateral Menière's disease: effects on vestibular function. Otolaryngol Head Neck Surg. 2005; 133(6):929-35. DOI: 10.1016/j.otohns.2005.07.033. View

Odkvist L, Bergenius J, Moller C . When and how to use gentamicin in the treatment of Menière's disease. Acta Otolaryngol Suppl. 1997; 526:54-7. DOI: 10.3109/00016489709124023. View

10.

Cohen-Kerem R, Kisilevsky V, Einarson T, Kozer E, Koren G, Rutka J . Intratympanic gentamicin for Menière's disease: a meta-analysis. Laryngoscope. 2004; 114(12):2085-91. DOI: 10.1097/01.mlg.0000149439.43478.24. View

11.

Kaplan D, Nedzelski J, Chen J, Shipp D . Intratympanic gentamicin for the treatment of unilateral Meniere's disease. Laryngoscope. 2000; 110(8):1298-305. DOI: 10.1097/00005537-200008000-00014. View

12.

Meyer J, Mack A, Gummer A . Pronounced infracuticular endocytosis in mammalian outer hair cells. Hear Res. 2001; 161(1-2):10-22. DOI: 10.1016/s0378-5955(01)00338-0. View

13.

Dulon D, Hiel H, Aurousseau C, Erre J, Aran J . Pharmacokinetics of gentamicin in the sensory hair cells of the organ of Corti: rapid uptake and long term persistence. C R Acad Sci III. 1993; 316(7):682-7. View

14.

Chia S, Gamst A, Anderson J, Harris J . Intratympanic gentamicin therapy for Ménière's disease: a meta-analysis. Otol Neurotol. 2004; 25(4):544-52. DOI: 10.1097/00129492-200407000-00023. View

15.

Hibi T, Suzuki T, Nakashima T . Perilymphatic concentration of gentamicin administered intratympanically in guinea pigs. Acta Otolaryngol. 2001; 121(3):336-41. DOI: 10.1080/000164801300102699. View

16.

Wu I, Minor L . Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease. Laryngoscope. 2003; 113(5):815-20. DOI: 10.1097/00005537-200305000-00009. View

17.

Steyger P, Peters S, Rehling J, Hordichok A, Dai C . Uptake of gentamicin by bullfrog saccular hair cells in vitro. J Assoc Res Otolaryngol. 2003; 4(4):565-78. PMC: 3202742. DOI: 10.1007/s10162-003-4002-5. View

18.

Harner S, Driscoll C, Facer G, Beatty C, McDonald T . Long-term follow-up of transtympanic gentamicin for Ménière's syndrome. Otol Neurotol. 2001; 22(2):210-4. DOI: 10.1097/00129492-200103000-00016. View

19.

Rauch S, Oas J . Intratympanic gentamicin for treatment of intractable Meniere's disease: a preliminary report. Laryngoscope. 1997; 107(1):49-55. DOI: 10.1097/00005537-199701000-00012. View

20.

Atlas J, Parnes L . Intratympanic gentamicin titration therapy for intractable Meniere's disease. Am J Otol. 1999; 20(3):357-63. View